Literature DB >> 17522469

Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma.

Xiao-ping Chen1, Dao-yu Hu, Zhi-wei Zhang, Bi-xiang Zhang, Yi-fa Chen, Wan-guang Zhang, Fa-zu Qiu.   

Abstract

BACKGROUND: The role of preoperative transcatheter arterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) was controversial.
METHODS: 246 patients with large centrally located HCC underwent mesohepatectomy (MH) and were divided into two groups: group A, 89 patients with preoperative TACE; group B, 157 patients without preoperative TACE. The aim was to evaluate the influence of preoperative TACE on postoperative complications and long-term results of patients with large centrally located HCC.
RESULTS: In the 89 patients of the TACE-MH group, a total of 123 (mean 1.4 per patient) preoperative TACEs were performed. The differences in postoperative complications (34.8 vs. 24.2%; p=0.075) and overall hospital mortality (3.4 vs. 0.6%; p=0.103) between the two groups were not significant. The postoperative recurrence rate in the remnant liver was higher in the MH group than in the TACE-MH group (79.6 vs. 73.0%), while the extrahepatic metastasis rate in the TACE-MH group was higher than that in the MH group (11.1 vs. 7.0%). Overall 1-, 3-, and 5-year survival rates were 87.1, 62.9, and 46.2%, respectively, for the TACE-MH group, and 82.2, 54.4, and 31.7%, respectively, for the MH group (p=0.001); 1-, 3-, and 5-year disease-free survival rates were 75.0, 46.2, and 31.8%, respectively, for the TACE-MH group, and 69.6, 38.0, and 16.5%, respectively, for the MH group (p=0.002).
CONCLUSIONS: Long-term outcomes of patients with preoperative TACE were improved and the pattern of the recurrences after surgery was altered. The patients with large centrally located HCC could benefit more from this neoadjuvant treatment, although there was some influence of preoperative TACE on postoperative complications. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17522469     DOI: 10.1159/000102901

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  17 in total

1.  Central Hepatectomy Still Plays an Important Role in Treatment of Early-Stage Centrally Located Hepatocellular Carcinoma.

Authors:  Chun-Han Chen; Tzu-Hao Huang; Cheng-Chih Chang; Wei-Feng Li; Ting-Lung Lin; Chih-Chi Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  Central hepatectomy for centrally located malignant liver tumors: A systematic review.

Authors:  Ser Yee Lee
Journal:  World J Hepatol       Date:  2014-05-27

3.  Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.

Authors:  Chao Li; Ming-Da Wang; Lun Lu; Han Wu; Jiong-Jie Yu; Wan-Guang Zhang; Timothy M Pawlik; Yao-Ming Zhang; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Hao Xing; Zhen-Li Li; Wan Yee Lau; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Hepatol Int       Date:  2019-09-05       Impact factor: 6.047

Review 4.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 5.  Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis.

Authors:  Wei Liu; Jian-Guo Zhou; Yi Sun; Lei Zhang; Bao-Cai Xing
Journal:  J Gastrointest Surg       Date:  2015-05-06       Impact factor: 3.452

6.  Ventral segment-preserving right hepatectomy in patients with hepatocellular carcinoma.

Authors:  Jin Hong Lim; Gi Hong Choi; Sung Hoon Choi; Hyung Soon Lee; Kyung Sik Kim; Jin Sub Choi
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

Review 7.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

8.  Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients.

Authors:  Mahesh Goel; Vinay Gaikwad; Tejas Dharia; Suyash Kulkarni; Nitin Shetty; Shailesh V Shrikhande
Journal:  Indian J Gastroenterol       Date:  2014-07-19

9.  Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma.

Authors:  Yanming Zhou; Xiaofeng Zhang; Lupeng Wu; Feng Ye; Xu Su; Lehua Shi; Bin Li
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

Review 10.  Current status of multimodal & combination therapy for hepatocellular carcinoma.

Authors:  Jian Yang; Lunan Yan; Wentao Wang
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.